GENinCode slumps after it reprices options

Shares in GENinCode, the AIM-listed cardiovascular genetics company, fell 12% to 1.08p after the company replaced director and employee share options at a lower exercise price, highlighting the scale of the stock's decline over the past year.

The company has granted 83.85 million new options at an exercise price of 1p a share, replacing 29.86 million existing options that were originally issued in March 2025 at 3.7p.

The board said the repricing was necessary to properly incentivise staff and reflect the company's current share price.

The new options vest over 24 months and are exercisable from the second anniversary of the grant, with a 10-year term.

Year-to-date, the stock is off 52%.